Bend Research Expands Analytical Sciences Capabilities
News May 15, 2013
Coupled with the company’s existing analytical-method development capabilities, Bend Research has added on-site stability storage and additional GMP testing to efficiently support manufacture of high-quality supplies for clinical use.
The new onsite stability storage will reduce the need to ship samples to a subcontractor, offering clients the enhanced effectiveness of a single vendor. Formulations can be stored at conditions ranging from 5⁰C to 40⁰C/75% RH, meeting industry-standard stability-testing conditions suggested by the International Conference on Harmonization (ICH).
“Our customers asked us to add this on-site capability and we were happy to provide the service. Having this capability on-site will reduce the risks associated with stability sample shipment. It also provides our clients with more rapid product testing and more control,” said Tanya Hayden, Bend Research Vice President.
In addition to stability and release testing, Bend Research continues to offer analytical-method development and method validation for drug products and intermediates in a world-class Quality Control laboratory. The company recently added instrumentation to its existing suite of GMP-qualified equipment. The new instruments, which include a differential scanning calorimeter (DSC) and Malvern particle-size analyzer, will increase capacity and offer clients additional GMP testing options in a single laboratory.
According to Hayden, this expansion is part of a continuing effort by Bend Research to offer its clients quick-to-clinic, full-service analytical capabilities, from drug concept to commercialization.
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Sequencing Shows How Evolution Can Undermine Bioprocess CommercializationNews
Rapid evolution can suppress the effect of pro-production genes in biochemical processes.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018